Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma:...

Area of Science:

• Oncology
• Pharmacology
• Neurology

Background:

• Lenalidomide is an immunomodulatory drug used in multiple myeloma therapy.
• Evidence regarding lenalidomide's neurotoxicity compared to thalidomide is limited.
• Chemotherapy-induced peripheral neuropathy (CIPN) is a common concern in myeloma patients.

Purpose of the Study:

• To prospectively assess the safety and neurotoxicity of lenalidomide in multiple myeloma patients.
• To evaluate lenalidomide's effect on pre-existing chemotherapy-induced peripheral neuropathy (CIPN).

Main Methods:

• Prospective study of 30 consecutive myeloma patients starting lenalidomide.
• Assessment using Total Neuropathy Score clinical version (TNSc), ECOG performance status, and NRS for pain at baseline, 6, and 12 months.
• CIPN defined as TNSc >2; clinically relevant change as >=4 points from baseline.

Main Results:

• At baseline, 53.3% of patients had pre-existing CIPN (mean TNSc 5.8).
• After 12 months, no new cases of significant neuropathy developed, and existing CIPN remained stable or improved.
• Numeric Rating Scale (NRS) for pain and ECOG performance status remained unchanged throughout the study.

Conclusions:

• Lenalidomide demonstrates a favorable safety profile with very low neurotoxicity in multiple myeloma patients.
• The drug is safe for patients with pre-existing CIPN, with no significant worsening observed over one year.
• Lenalidomide can be considered a safe therapeutic option for relapsed or refractory myeloma, even in patients with prior neuropathy.